The Clinical Prediction Value of the Ubiquitination Model Reflecting the Immune Traits in LUAD

Abstract

BackgroundIncreasing evidence shows that the ubiquitin–proteasome system has a crucial impact on lung adenocarcinoma. However, reliable prognostic signatures based on ubiquitination and immune traits have not yet been established.MethodsBioinformatics was performed to analyze the characteristic of ubiquitination in lung adenocarcinoma. Principal component analysis was employed to identify the difference between lung adenocarcinoma and adjacent tissue. The ubiquitin prognostic risk model was constructed by multivariate Cox regression and least absolute shrinkage and selection operator regression based on the public database The Cancer Genome Atlas, with evaluation of the time-dependent receiver operating characteristic curve. A variety of algorithms was used to analyze the immune traits of model stratification. Meanwhile, the drug response sensitivity for subgroups was predicted by the “pRRophetic” package based on the database of the Cancer Genome Project.ResultsThe expression of ubiquitin genes was different in the tumor and in the adjacent tissue. The ubiquitin model was superior to the clinical indexes, and four validation datasets verified the prognostic effect. Additionally, the stratification of the model reflected distinct immune landscapes and mutation traits. The low-risk group was infiltrating plenty of immune cells and highly expressed major histocompatibility complex and immune genes, which illustrated that these patients could benefit from immune treatment. The high-risk group showed higher mutation and tumor mutation burden. Integrating the tumor mutation burden and the immune score revealed the patient’s discrepancy between survival and drug response. Finally, we discovered that the drug targeting ubiquitin and proteasome would be a beneficial prospective treatment for lung adenocarcinoma.ConclusionThe ubiquitin trait could reflect the prognosis of lung adenocarcinoma, and it might shed light on the development of novel ubiquitin biomarkers and targeted therapy for lung adenocarcinoma.

Prognostic implication and immunotherapy response prediction of a ubiquitination-related gene signature in breast cancer

“…Ubiquitination could be considered an essential hallmark of cancer; hence, it has been extensively investigated in previous studies using statistical tests and machine learning to integrate transcriptomics and ubiquitination into the underlying molecular mechanisms, with significant benefits ( Popovic et al, 2014 ; Ge et al, 2018 ). Aberrant ubiquitination could underlie some of the heterogeneity of lung cancer, and drugs that target ubiquitin could offer effective new cancer treatments ( Che et al, 2022 ). Thus, it is important to identify robust tumor-associated ubiquitination biomarkers, which could not only improve BC diagnosis and prognosis but also help develop novel therapeutic strategies.…”

Prognostic significance and identification of basement membrane-associated lncRNA in bladder cancer

“…After downloading data from the Genomics of Cancer Drug Sensitivity (GDSC) database, the R package pRRophetic was used to analyze the half-maximal inhibitory concentration (IC50) of each BCa patient and the drug to predict treatment response ( 23 ).…”

Identification of a Prognostic Model Based on Immune Cell Signatures in Clear Cell Renal Cell Carcinoma

“…Genomics of Drug Sensitivity in Cancer (GDSC) ( https://www.cancerrxgene.org/ ) was a publicly available pharmacogenomic database to study the drug sensitivity of cancer cells, which could present a distinct resource for the discovery of new targets for cancer therapy [ 21 ]. Half-maximal inhibitory concentrations (IC50) of common chemotherapeutic agents were estimated by the “pRRophetic” package [ 22 ].…”

“…Oxidative Medicine and Cellular Longevity concentrations (IC50) of common chemotherapeutic agents were estimated by the "pRRophetic" package [22].…”